From looking at the program, there were only 2 accepted oral papers for the Cancer of the Pancreas session - the rest are invited or panel discussions.
So,that's excellent.
Also I note a panel discussion on borderline resectable/non-resectable definitions, which would go a long way toward addressing the appropriate patient groups for oncosil treatment in future studies.
Ann: OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC, page-5
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.1¢ | $65.61K | 5.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 6553895 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1917493 | 5 |
View Market Depth
| Last trade - 15.50pm 16/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |